Breakthrough study reveals gene drivers specific to Asian lung cancers
Findings from this landmark study, which were published in February 2020’s issue of Nature Genetics, are expected to contribute to the development of personalised medicine for lung cancer treatment and prevention.
Singapore scientists reported that Asian lung adenocarcinoma (LUAD) displays a distinctive mutational landscape and a novel inflammatory subtype, offering new insights for precision immunotherapy.
The discovery of Asian‑specific mutational patterns and an inflammatory LUAD subtype could refine patient stratification and improve the efficacy of immunotherapies tailored to East Asian populations.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT